S1: What ACTUALLY Starts The Process of Heart Disease?
Is heart disease driven by circulating ApoB particles, or is it inflammation or insulin reisstance? In this video, I break down the vascular biology of atherosclerosis from endothelial transcytosis and matrix retention to insulin resistance and inflammation. Let's move past the online tribalism and look at what the science actually shows about how plaque begins.
Stop stressing over every health detail & start living! My FREE 'Necessary Nine' PDF cuts through the noise, giving you the essential things you need for a healthy life. ➡️ Download Here: https://www.jrennickemd.com/necessaryninepdf
CHAPTERS:00:00 - Intro01:08 - Artery Anatomy: The Intima & Subendothelium02:05 - The Endothelial Glycocalyx03:13 - Passive Leak vs. Active Transcytosis04:28 - Particle Entry vs. Particle Retention05:16 - What Plaque Pathology Actually Shows06:11 - Steel-Manning Camp A: The ApoB Hypothesis07:50 - The Mutated ApoB Mouse Experiment08:44 - The Lipoprotein Lipase Plot Twist10:06 - LDL Particle Count vs. Particle Size11:22 - Why Are Veins and Internal Mammary Arteries Protected?13:17 - Steel-Manning Camp B: The Inflammatory Model14:31 - Insulin Resistance & Artery Wall Changes15:32 - Endothelial Insulin Signaling & The IRIS Trial17:40 - The Artery Wall Matrix: How Retention Happens19:12 - Can Native LDL Form Foam Cells?21:12 - The Seed and Soil Model of Atherosclerosis22:48 - Clinical Reality vs. Internet Dogma24:41 - The Collision of Particle, Wall, and Time
SELECTED REFERENCES:10.1093/eurheartj/ehz962 (Borén 2020, EAS consensus statement)10.1161/CIRCULATIONAHA.106.676890 (Tabas 2007, response-to-retention update)10.1161/ATVBAHA.106.134080 (Nakashima 2007, early human lesions)10.2337/diabetes.55.02.06.db05-1103 (Nieuwdorp 2006, hyperglycemia and glycocalyx)10.1093/cvr/cvv218 (Armstrong 2015, LDL transcytosis)10.1056/NEJMoa054013 (Cohen 2006, PCSK9 variants)10.1093/eurheartj/ehx144 (Ference 2017, EAS genetic and trial evidence)10.1038/nature00804 (Skålén 2002, mutated ApoB mice)10.1161/CIRCRESAHA.107.149666 (Gustafsson 2007, lipoprotein lipase follow-up)https://pubmed.ncbi.nlm.nih.gov/40289348/ (Morze 2025, UK Biobank particle count vs. size)10.1161/ATVBAHA.121.316256 (Kraler 2021, internal mammary artery resistance)10.1056/NEJMoa1707914 (Ridker 2017, CANTOS)10.1056/NEJMoa2021372 (Nidorf 2020, LoDoCo2)10.1016/j.cmet.2010.03.013 (Rask-Madsen 2010, endothelial insulin receptor knockout)10.2337/diabetes.52.2.453 (Garvey 2003, insulin resistance and LDL particle number)10.1056/NEJMoa1506930 (Kernan 2016, IRIS)https://pubmed.ncbi.nlm.nih.gov/28550710/ (Hagensen 2017, diabetes and LDL retention in mice)https://pubmed.ncbi.nlm.nih.gov/15533943/ (Kruth 2005, macropinocytosis of native LDL)https://pubmed.ncbi.nlm.nih.gov/16606620/ (Zhao 2006, receptor-independent LDL uptake by human macrophages)https://pubmed.ncbi.nlm.nih.gov/36130017/ (Lin 2022, fluid-phase macropinocytosis and atherosclerosis)https://pubmed.ncbi.nlm.nih.gov/24481950/ (Allahverdian 2014, smooth muscle–derived foam cells in human plaque)
*Disclaimer* This podcast is for entertainment, education, and informational purposes only. The topics discussed should not solely be used to diagnose, treat , or prevent any condition. The information presented here was created with an evidence based approach, but you please keep in mind that science is always changing and at the time of listening to this there may some new data that makes this information incomplete or inaccurate. Always seek the advice of your personal physician or qualified health care provider for questions regarding any medical condition.